News | January 22, 2014

Elixir Completes First Commercial Implant Of Fully Bioresorbable Stent

Patient in Germany receives fully bioresorbable scaffold designed to degrade in one year

Elixir Medical DESolve Bioresorbable Coronary Scaffold System Stents
January 22, 2014 — The first commercial implant of Elixir Medical’s CE Mark-approved DESolve Novolimus Eluting Coronary Scaffold was performed in Germany by Prof. Dr. med. Holger Nef, head of the Cardiac Catheterization Laboratory, University Hospital Giessen, Giessen, Germany.
 
Elixir’s fully bioresorbable DESolve scaffold for coronary artery disease restores blood flow to the heart like metallic stents and then dissolves, resulting in a functional artery free of a permanent implant. Developed from a poly-L Lactide (PLLA)-based polymer, DESolve attempts to provide strength and support to arteries while delivering the anti-proliferative drug, Novolimus. It intends to maintain radial strength and vessel support during healing while degrading in one year, increase lumen area within six months, self-appose to the vessel wall up to the nominal deployed diameter and provide a wide margin of expansion.
 
“The fully bioresorbable DESolve System is easy to deliver. The acute performance of the scaffold demonstrated excellent stent apposition to the vessel wall and low recoil, and the patient is doing well,” Nef said.
 
The DESolve Nx pivotal trial enrolled 126 patients at 13 centers in Europe, Brazil and New Zealand. 1-year safety and efficacy results for the DESolve Novolimus Eluting Coronary Scaffold System were announced at the October 2013 Transcatheter Therapeutics scientific conference in San Francisco. At that time, the DESolve Nx trial had demonstrated a low Major Adverse Cardiac Events (MACE) rate of 5.69 percent with no definite scaffold thrombosis. 
 
The fully bioresorbable DESolve Novolimus Eluting Scaffold System is currently available in diameters of 3.0, 3.25 and 3.5 mm and lengths of 14, 18 and 28 mm. Additional sizes will be available in 2014.
 
For more information: www.elixirmedical.com

Related Content

Videos | Stents Bioresorbable| November 07, 2017
A discussion with Ajay Kirtane, M.D., SM, director of the cardiac catheterization laboratories at New York-Presbyteri
Thirty-Day ABSORB IV Results Demonstrate Improvements Still Needed in Bioresorbable Stents
News | Stents Bioresorbable| October 31, 2017
Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular scaffold (BVS)...
Amaranth Medical to Share Bioresorbable Scaffold Data at TCT
News | Stents Bioresorbable| October 25, 2017
Amaranth Medical will provide an update at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting, Oct. 29-...
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
BVS, Absorb stent, bioresorbable scaffold, ABSORB III data, ABSORB III results
Feature | Stents Bioresorbable| March 21, 2017 | Dave Fornell
March 21, 2017 — In the late-breaking ABSORB III Trial two year results presented at the American College of Cardiolo
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Videos | Stents Bioresorbable| November 09, 2016
Juan Granada, M.D., executive director and chief scientific officer of the Cardiovascular Research Foundation's Skirb
Fortitude bioresorbable stent

The Fortitude sirolimus-eluting bioresorbable stent.

 

News | Stents Bioresorbable| November 07, 2016
The 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 3 in Washington, D.C...
Overlay Init